Your browser doesn't support javascript.
loading
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia.
Doucette, Kimberley; Percival, Mary-Elizabeth; Williams, Lacey; Kandahari, Adrese; Taylor, Allison; Wang, Shuqi; Ahn, Jaeil; Karp, Judith E; Lai, Catherine.
Afiliação
  • Doucette K; Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Percival ME; Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Williams L; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Kandahari A; Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Taylor A; Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Wang S; Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Ahn J; Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Karp JE; Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Lai C; Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
Hematol Oncol ; 39(5): 697-706, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34499366
Older age and poor performance status lead to worse outcomes in acute myeloid leukemia (AML) patients. Hypoalbuminemia is a negative predictor of morbidity and mortality in several malignancies. We evaluated the relationship between baseline serum albumin levels on treatment-related complications, as well as short-term mortality and overall survival (OS) in 756 newly diagnosed AML patients. We conducted a retrospective multicenter study to examine treatment-related complications and OS according to pretreatment serum albumin levels: normal albumin ≥3.5 g/dl, marked hypoalbuminemia <2.5 g/dl, and hypoalbuminemia 2.5-3.4 g/dl. In an adjusted multivariate analysis, a lower baseline albumin was independently associated with a higher number of grade ≥3 complications when adjusting for age, secondary AML, sex and intensive treatment. When comparing normal to markedly low albumin levels, the estimated mean number of complications increases by a factor of 1.35. Patients who had a normal baseline albumin had a 30 day-mortality rate of 4.8%, which was significantly lower compared with patients with hypoalbuminemia (16.5%) and marked hypoalbuminemia (33.9%; p < 0.01). Similarly, 60-day mortality rate was significantly higher in the hypoalbuminemia group (24.0%) and marked hypoalbuminemia group (45%) compared with normal albumin group (8.3%; p < 0.01). Patients with lower baseline albumin levels have increased treatment-related morbidity and mortality, suggesting that pre-treatment serum albumin is an important independent prognostic marker.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Albumina Sérica / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Hipoalbuminemia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Albumina Sérica / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Hipoalbuminemia Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos